Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Datian Chen, Kaikai Gu & Huiyu Wang. (2019) Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. Cancer Management and Research 11, pages 1705-1716.
Read now
Read now
Martin Reck, Anders Mellemgaard, Silvia Novello, Pieter E Postmus, Birgit Gaschler-Markefski, Rolf Kaiser & Hannes Buchner. (2018) Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. OncoTargets and Therapy 11, pages 4573-4582.
Read now
Read now
Yoshihito Ohhara, Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma & Toshiharu Yamaguchi. (2015) Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. OncoTargets and Therapy 8, pages 529-537.
Read now
Read now
Piercarlo Saletti, Francesca Molinari, Sara De Dosso & Milo Frattini. (2015) EGFR signaling in colorectal cancer: a clinical perspective. Gastrointestinal Cancer: Targets and Therapy 5, pages 21-38.
Read now
Read now
Miguel Jhonatan Sotelo Lezama, Javier Sastre Valera & Eduardo Díaz-Rubio García. (2014) Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy 14:3, pages 387-399.
Read now
Read now
Articles from other publishers (46)
Xiang-Yu Wang, Rui Zhang, Jia-Hao Han, Shi-Qing Chen, Fei-Long Zhao, Hui Chen, Jing Lin, Jie Fan, Wen-Wei Zhu, Lu Lu & Jin-Hong Chen. (2023) Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study. Annals of Surgical Oncology 30:8, pages 5252-5263.
Crossref
Crossref
Tomoyuki Nagaoka, Hiroki Osumi, Teruko Ueno, Akira Ooki, Takeru Wakatsuki, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kiyoshi Matsueda, Kensei Yamaguchi & Eiji Shinozaki. (2023) Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab. International Journal of Clinical Oncology.
Crossref
Crossref
Takashi Ura, Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa, Ken Kato, Takahiro Tsushima, Kunihiro Fushiki, Keisho Chin, Akihisa Tomori, Tatsuya Okuno, Hisayuki Matsushita, Takashi Kojima, Yuichiro Doki, Hitoshi Kusaba, Kazumasa Fujitani, Shiko Seki & Yuko Kitagawa. (2022) Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus 20:2, pages 272-280.
Crossref
Crossref
Greta Sommerhäuser, Annika Kurreck, Alexander Beck, Uli Fehrenbach, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Mueller, Alexander O. Koenig, Ludwig F. v. Weikersthal, Eray Goekkurt, Siegfried Haas, Arndt Stahler, Volker Heinemann, Swantje Held, Annabel H.S. Alig, Stefan Kasper, Sebastian Stintzing, Tanja Trarbach & Dominik P. Modest. (2023) Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). European Journal of Cancer 178, pages 37-48.
Crossref
Crossref
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto & Kensei Yamaguchi. (2022) Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. BMC Cancer 22:1.
Crossref
Crossref
Bernhard Doleschal, Andreas Petzer & Holger Rumpold. (2022) Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Frontiers in Oncology 12.
Crossref
Crossref
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Kathrin Heinrich, Swantje Held, Arndt Stahler, Annabel Helga Sophie Alig, Ivan Jelas, Jobst C. von Einem, Sebastian Stintzing, Clemens Giessen-Jung & Dominik P. Modest. (2022) Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial. Frontiers in Oncology 12.
Crossref
Crossref
Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kodera, Masato Nakamura, Takako Eguchi Nakajima, Yoshinori Miyata, Toshikazu Moriwaki, Tetsuya Kusumoto, Kazuo Nishikawa, Kazuhiro Ogata, Masashi Shimura, Satoshi Morita & Wasaburo Koizumi. (2020) Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer 24:2, pages 467-476.
Crossref
Crossref
Naoki Izawa, Kohei Shitara, Kimio Yonesaka, Takeharu Yamanaka, Takayuki Yoshino, Yu Sunakawa, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Ichinosuke Hyodo, Kei Muro & Takako Eguchi Nakajima. (2020) Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). Targeted Oncology 15:5, pages 623-633.
Crossref
Crossref
A. Kurreck, M. Geissler, U. M. Martens, J. Riera-Knorrenschild, J. Greeve, A. Florschütz, S. Wessendorf, T. Ettrich, S. Kanzler, D. Nörenberg, M. Seidensticker, S. Held, P. Buechner-Steudel, J. Atzpodien, V. Heinemann, S. Stintzing, T. Seufferlein, A. Tannapfel, A. C. Reinacher-Schick & D. P. Modest. (2020) Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). Journal of Cancer Research and Clinical Oncology 146:10, pages 2681-2691.
Crossref
Crossref
Nuri Faruk Aykan & Tahsin Özatlı. (2020) Objective response rate assessment in oncology: Current situation and future expectations. World Journal of Clinical Oncology 11:2, pages 53-73.
Crossref
Crossref
J.W. Holch, S. Held, S. Stintzing, L. Fischer von Weikersthal, T. Decker, A. Kiani, F. Kaiser, T. Heintges, C. Kahl, F. Kullmann, W. Scheithauer, M. Moehler, J.C. von Einem, M. Michl & V. Heinemann. (2020) Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Annals of Oncology 31:1, pages 72-78.
Crossref
Crossref
Julien Taieb, Michael Geissler, Fernando Rivera, Meinolf Karthaus, Richard Wilson, Fotios Loupakis, Timothy Price, Michael Tracy, Peter Burdon & Marc Peeters. (2019) Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer 18:4, pages 245-256.e5.
Crossref
Crossref
Giuseppe A. Colloca, Antonella Venturino & Domenico Guarneri. (2019) Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer. International Journal of Clinical Oncology 24:11, pages 1406-1411.
Crossref
Crossref
Lola-Jade Palmieri, Amina Fihri, Solène Doat, Olivier Dubreuil, Gilles Manceau, Mehdi Karoui, Mathilde Wagner, Olivier Lucidarme & Jean-Baptiste Bachet. (2019) Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. European Radiology 29:7, pages 3871-3880.
Crossref
Crossref
Giuseppe A. Colloca, Antonella Venturino & Domenico Guarneri. (2019) Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis. International Journal of Clinical Oncology 24:3, pages 231-240.
Crossref
Crossref
Felix Che-Lok Chow & Kenneth Siu-Ho Chok. (2019) Colorectal liver metastases: An update on multidisciplinary approach. World Journal of Hepatology 11:2, pages 150-172.
Crossref
Crossref
Yuwen Zhou, Jing Zhang, Dan Pu, Feng Bi, Ye Chen, Jiyan Liu, Qiu Li, Hongfeng Gou, Bing Wu & Meng Qiu. (2019) Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Anti-Cancer Drugs 30:2, pages 195-200.
Crossref
Crossref
Tomohiro Nishina, Mizutomo Azuma, Kazuhiro Nishikawa, Masahiro Gotoh, Hideaki Bando, Naotoshi Sugimoto, Kenji Amagai, Keisho Chin, Yasumasa Niwa, Akihito Tsuji, Hiroshi Imamura, Masahiro Tsuda, Hirofumi Yasui, Hirofumi Fujii, Kensei Yamaguchi, Hisateru Yasui, Shuichi Hironaka, Ken Shimada, Hiroto Miwa, Terukazu Mitome, Hiroki Kageyama & Ichinosuke Hyodo. (2018) Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Gastric Cancer 22:1, pages 138-146.
Crossref
Crossref
Ajlan Atasoy & Murielle Mauer. 2019. Textbook of Gastrointestinal Oncology. Textbook of Gastrointestinal Oncology
493
507
.
Peng Zheng, Chunmin Liang, Li Ren, Dexiang Zhu, Qingyang Feng, Wenju Chang, Guodong He, Lechi Ye, Jingwen Chen, Qi Lin, Tuo Yi, Meiling Ji, Zhengchuan Niu, Mi Jian, Ye Wei & Jianmin Xu. (2018) Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of Oncology 2018, pages 1-14.
Crossref
Crossref
Thibault Mazard, Piyaporn Boonsirikamchai, Michael J Overman, Mohamed A Asran, Haesun Choi, Delise Herron, Cathy Eng, Dipen M Maru, Marc Ychou, Jean-Nicolas Vauthey, Evelyne M Loyer & Scott Kopetz. (2018) Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut 67:6, pages 1095-1102.
Crossref
Crossref
Julien Taieb, Fernando Rivera, Salvatore Siena, Meinolf Karthaus, Manuel Valladares-Ayerbes, Javier Gallego, Michael Geissler, Reija Koukakis, Gaston Demonty & Marc Peeters. (2017) Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology 144:2, pages 321-335.
Crossref
Crossref
Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Gr?valos, Pilar Escudero, Federico Longo-Mu?oz, Jos?-Luis Manzano, Auxiliadora G?mez, Mar?a Jos? Safont, Javier Gallego, Beatriz Garc?a-Paredes, Carles Pericay, Rosario Due?as, Fernando Rivera, Ferr?n Losa, Manuel Valladares-Ayerbes, Encarnaci?n Gonz?lez & Enrique Aranda. (2017) First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer 81, pages 191-202.
Crossref
Crossref
Choong-Kun Lee, Seung-Seob Kim, Saemi Park, Chan Kim, Su Jin Heo, Joon Seok Lim, Hyunki Kim, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Sohee Park & Minkyu Jung. (2017) Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget 8:19, pages 31169-31179.
Crossref
Crossref
Dominik P. Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Werner Scheithauer, Thomas Kirchner, Andreas Jung, Martina Stauch, Jobst Christian von Einem, Markus Moehler, Swantje Held & Volker Heinemann. (2017) Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306). International Journal of Cancer 140:8, pages 1918-1925.
Crossref
Crossref
Jing Hu, Zhen Zhang, Rui Zheng, Lei Cheng, Mi Yang, Li Li, Baorui Liu & Xiaoping Qian. (2016) On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis. Cancer Chemotherapy and Pharmacology 79:2, pages 275-285.
Crossref
Crossref
Kentaro Sakamaki, Yosuke Kito, Kentaro Yamazaki, Naoki Izawa, Takashi Tsuda, Satoshi Morita & Narikazu Boku. (2017) Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. ESMO Open 2:5, pages e000275.
Crossref
Crossref
Akihito Tsuji, Yu Sunakawa, Wataru Ichikawa, Masato Nakamura, Mitsugu Kochi, Tadamichi Denda, Tatsuro Yamaguchi, Ken Shimada, Akinori Takagane, Satoshi Tani, Masahito Kotaka, Hidekazu Kuramochi, Kaoru Furushima, Junichi Koike, Yutaka Yonemura, Masahiro Takeuchi, Masashi Fujii & Toshifusa Nakajima. (2016) Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05). Targeted Oncology 11:6, pages 799-806.
Crossref
Crossref
Mohamed Bouchahda, Valérie Boige, Denis Smith, Abdoulaye Karaboué, Michel Ducreux, Mohamed Hebbar, Céline Lepère, Christian Focan, Rosine Guimbaud, Pasquale Innominato, Sameh Awad, Carlos Carvalho, Salvatore Tumolo, Stephanie Truant, Thierry De Baere, Denis Castaing, Philippe Rougier, Jean-François Morère, Julien Taieb, René Adam & Francis Lévi. (2016) Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer 68, pages 163-172.
Crossref
Crossref
Goro Nakayama, Tsutomu Fujii, Kenta Murotani, Keisuke Uehara, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Daisuke Kobayashi, Mitsuro Kanda, Suguru Yamada, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yuichi Ando & Yasuhiro Kodera. (2016) Modified two‐dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Science 107:10, pages 1492-1498.
Crossref
Crossref
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, Markus M Lerch, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Giessen-Jung, Markus Moehler, Andreas Jagenburg, Thomas Kirchner, Andreas Jung & Volker Heinemann. (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. The Lancet Oncology 17:10, pages 1426-1434.
Crossref
Crossref
Qingyang Feng, Ye Wei, Li Ren, Peng Zheng, Yiyi Yu, Qinghai Ye, Jianyong Ding, Jingwen Chen, Wenju Chang, Yunshi Zhong, Dexiang Zhu, Qi Lin, Liangliang Yang, Xinyu Qin & Jianmin Xu. (2016) Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget 7:10.
Crossref
Crossref
Mariko Kobayashi, Shinji Endo, Yukako Hamano, Mamiko Imanishi, Daisuke Akutsu, Akinori Sugaya, Daisuke Ochi, Toshikazu Moriwaki & Ichinosuke Hyodo. (2016) Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis. Internal Medicine 55:2, pages 127-130.
Crossref
Crossref
Seung Tae Kim, Kee-Taek Jang, Su Jin Lee, Hye-Lim Jang, Jeeyun Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang & Joon Oh Park. (2015) Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer 15:1.
Crossref
Crossref
René Adam, Aimery de Gramont, Joan Figueras, Norihiro Kokudo, Francis Kunstlinger, Evelyne Loyer, Graeme Poston, Philippe Rougier, Laura Rubbia-Brandt, Alberto Sobrero, Catherine Teh, Sabine Tejpar, Eric Van Cutsem, Jean-Nicolas Vauthey & Lars Påhlman. (2015) Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treatment Reviews 41:9, pages 729-741.
Crossref
Crossref
Giuseppe Aprile, Caterina Fontanella, Marta Bonotto, Karim Rihawi, Stefania Eufemia Lutrino, Laura Ferrari, Mariaelena Casagrande, Elena Ongaro, Massimiliano Berretta, Antonio Avallone, Gerardo Rosati, Francesco Giuliani & Gianpiero Fasola. (2015) Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 6:30, pages 28716-28730.
Crossref
Crossref
Volker Heinemann, Sebastian Stintzing, Dominik P. Modest, Clemens Giessen-Jung, Marlies Michl & Ulrich R. Mansmann. (2015) Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). European Journal of Cancer 51:14, pages 1927-1936.
Crossref
Crossref
Jean-Yves Douillard, Salvatore Siena, Marc Peeters, Reija Koukakis, Jan-Henrik Terwey & Josep Tabernero. (2015) Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer 51:10, pages 1231-1242.
Crossref
Crossref
Fausto Petrelli, Filippo Pietrantonio, Chiara Cremolini, Maria Di Bartolomeo, Andrea Coinu, Veronica Lonati, Filippo de Braud & Sandro Barni. (2015) Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. European Journal of Cancer 51:7, pages 800-807.
Crossref
Crossref
Le-chi Ye, Ye Wei, De-xiang Zhu, Tao Chen & Jianmin Xu. (2015) Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. Journal of Gastroenterology and Hepatology 30:4, pages 674-679.
Crossref
Crossref
Takahiro UMEMOTO, Nobuyuki OHIKE, Kazuhiro KIJIMA, Masatsugu NAGAHAMA, Takashi KATO, Hiroshi TAKAHASHI & Jun-ichi TANAKA. (2015) A Case of Krukenberg Tumor Metastasized from Colon Cancer Subsequent to Synchronous Multiple Liver Metastasis. The Showa University Journal of Medical Sciences 27:4, pages 285-289.
Crossref
Crossref
Lei Cheng, Wei Ren, Li Xie, Ming Li, Jiang Liu, Jing Hu, Bao-Rui Liu & Xiao-Ping Qian. (2014) Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemotherapy and Pharmacology 74:1, pages 1-13.
Crossref
Crossref
Hiroki Yoshita, Ayumu Hosokawa, Akira Ueda, Takayuki Ando, Shinya Kajiura, Hiroshi Kato, Hideto Kawabe, Gakuto Tomizawa, Naoki Horikawa, Kazuhisa Yabuhita, Masayuki Note & Toshiro Sugiyama. (2014) Predictive Value of Optimal Morphologic Response to First-Line Chemotherapy in Patients with Colorectal Liver Metastases. Digestion 89:1, pages 43-48.
Crossref
Crossref
Le-chi Ye, Yun-shi Zhong, Qi Lin & Jianmin Xu. (2013) Reply to Y. Sunakawa et al and P. Mroczkowski et al. Journal of Clinical Oncology 31:35, pages 4474-4475.
Crossref
Crossref
M. Roos. (2012) Kolonkarzinom – Neue Biologicals, neue BiomarkerColon cancer: new biologicals, new biomarkers. Der Onkologe 18:11, pages 1035-1038.
Crossref
Crossref